Tonix Pharmaceuticals (TNXP) Expected to Announce Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) is projected to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($6.23) per share and revenue of $3.35 million for the quarter.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.23) by ($3.54). The company had revenue of $2.58 million during the quarter, compared to analyst estimates of $3.20 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Price Performance

TNXP stock opened at $15.64 on Friday. Tonix Pharmaceuticals has a 1 year low of $6.76 and a 1 year high of $672.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock has a market cap of $100.64 million, a price-to-earnings ratio of 0.00 and a beta of 2.23. The company has a 50 day simple moving average of $17.50 and a 200 day simple moving average of $20.23.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TNXP. Noble Financial reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th. StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating for the company.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.